Medtronic Diabetes - Healthcare Leadership Council ·

16
Medtronic Diabetes: Who We Are What We Do and Where are We Going Who We Are, What We Do and Where are We Going Robert A. Vigersky, M.D. Medical Director, Medtronic Diabetes P t P id tEd i S it Past-President, Endocrine Society Colonel (ret) U.S. Army Medical Corps May 18, 2015

Transcript of Medtronic Diabetes - Healthcare Leadership Council ·

Page 1: Medtronic Diabetes - Healthcare Leadership Council ·

Medtronic Diabetes: Who We Are What We Do and Where are We GoingWho We Are, What We Do and Where are We Going

Robert A. Vigersky, M.D.Medical Director, Medtronic Diabetes

P t P id t E d i S i tPast-President, Endocrine SocietyColonel (ret) U.S. Army Medical Corps

May 18, 2015

Page 2: Medtronic Diabetes - Healthcare Leadership Council ·

Medtronic: Global Medical Technology LeaderMedtronic: Global Medical Technology LeaderNumber of employees:

85,000+85,000Number of countries operating in:

160+160500,000+patientsNumber of patents:Number of patents:

53,000+Research and development spend:

$$2BCharitable contributions:

$80M$80MInformation reflects Medtronic fiscal year 2014 data and Covidien fiscal year 2014

data

Page 3: Medtronic Diabetes - Healthcare Leadership Council ·

Diabetes Care SolutionsDiabetes Care Solutions

Serving Insulin Pumps Continuous Glucose M it i

g500,000+patients

Monitoring

patients worldwide

ConnectedCare

Data Management

Slide 3 | Confidential

Care Management

Page 4: Medtronic Diabetes - Healthcare Leadership Council ·

Diabetes Care SolutionsDiabetes Care Solutions

“Artificial Pancreas”Closed LoopClosed Loop

I li P C i Gl M iInsulin Pump Continuous Glucose Monitor

Slide 4 | Confidential

Page 5: Medtronic Diabetes - Healthcare Leadership Council ·

Winning the Race to Closed LoopIntensive Insulin

Management

Winning the Race to Closed LoopHybrid Closed Loop

MiniMed 640GSmartGuard

MiniMed 530GThreshold Suspend

Stops insulin delivery when glucose levels fall

Stops insulin delivery when glucose levels are predicted to fall

Starts & stops insulin based on actual & e g ucose e e s a

below set thresholdare predicted to fall below set threshold

predicted values

Clinical Path: Continue pursuit of artificial pancreas

Consumer Path: Innovate around comfort, ease and cost across all segments

Page 6: Medtronic Diabetes - Healthcare Leadership Council ·

Personal and Professional Continuous Glucose Monitoring

Professional CGM Personal CGM

Guardian® CGM System

iPro®2

Page 7: Medtronic Diabetes - Healthcare Leadership Council ·

Personal and Professional Continuous Glucose Monitoring

Professional CGM Personal CGM

Guardian® CGM System

iPro®2

Page 8: Medtronic Diabetes - Healthcare Leadership Council ·

Looking Beyond A1C and BG Meter Readings

BG Meter Readings

CGM Reveals Insights Beyond BGs and A1C

l dMeter Avg: 100 SD: 40

SG A 154 SD 102

400

Continuous Glucose Sensor Readings

A1C: 7 5

SG Avg: 154 SD: 102

mg/

dL)

300

A1C: 7.5

Glu

cose

(

200

G

100

40

Target Glucose Range

9PM 6PM3PM12PM9AM6AM3AM

Time of Day

Midnight Midnight40

Page 9: Medtronic Diabetes - Healthcare Leadership Council ·

(2001) Kaufman Study

N b f Gl

( ) y

Study Design Study Duration: 6 months

Professional CGM Captures Excursions Missed by BG MetersOutcome

191

Number of Glucose Excursions Identified

Study Duration: 6 months

N: 47 pediatrics with type 1 Diabetes (A1C > 8.6%±1 1.6),

P f i l CGM( ),

intensive insulin therapy

3-day Professional CGM

Professional CGMBG Meter

7242

10

yevaluation and BG Meter Readings

Overall Night-time Compared highs and lows

identified with CGM versus BG

Professional CGM revealed up to 7x more night-time excursionsthan BG meters

Kaufman F, et. al. Diabetes Care. 2001;24(12):2030-4.

Page 10: Medtronic Diabetes - Healthcare Leadership Council ·

Clinicians used CGM data to adjust and optimize therapy

Professional CGM Helped Guide Bolus/Basal Therapy Modifications

Clinician Directed Change

Hypo treatment

Bolus or Rapid-acting Insulin

Basal or Long-acting Insulin

for Dawn Phenomenon

Correction Algorithm

Hypo treatment

for High Glycemic Foods

for High Fat Meals

for Dawn Phenomenon

Kaufman F, et. al. Diabetes Care. 2001;24(12):2030-4.

0% 10% 20% 30% 40% 50% 60% 70% 80% 90%

Page 11: Medtronic Diabetes - Healthcare Leadership Council ·

Personal and Professional Continuous Glucose Monitoring

Professional CGM Personal CGM

Guardian® CGM System

iPro®2

Page 12: Medtronic Diabetes - Healthcare Leadership Council ·

Personal Continuous Glucose Monitoring in Type 1 DM

Bailey TS et al. Diab Tech Ther 9:203-210, 2007

Page 13: Medtronic Diabetes - Healthcare Leadership Council ·

Personal Continuous Glucose Monitoring in Type 2 DM

Vigersky R. et al. Diab Care 35: 32-38, 2012

Page 14: Medtronic Diabetes - Healthcare Leadership Council ·

Driving Technology Breakthroughs Tomorrow

REDESIGN

Driving Technology BreakthroughsHybrid closed-loop system

Artificial pancreasToday

ump

and

CG

M

2014

Artificial pancreas

CGM for Type 2 in Primary Care

stin

tegr

ated

pu 2015

2013Yesterday

MiniMed 620G CG

M

1sMiniMed 640GSmartGuard technology

522/722MiniMed 530G

MiniMed 620G

stin

sulin

pum

p

pro

CG

M

1stre

al-ti

me

1st system to automatically

New pump platform in Japan

2003

2006502

1s 1st suspend insulin in U.S.

19831999

2003

This slide contains future products/technologies that are not available for commercial distribution...

Page 15: Medtronic Diabetes - Healthcare Leadership Council ·

The Medicare CGM Access Act of 2015, HR 1427

Creates Medicare Access for CGM • Stand-alone, SAP, APDSStand alone, SAP, APDS• Covers medically appropriate

populations

Establish Appropriate payment mechanism for CGM

P th f f t t h l• Pathway for future technology (APDS)

S t d H BillSenate and House Bills• H.R. 1427 Reps. Tom Reed, Diana

DeGette, and Ed Whitfield

• S. 804 Senators Susan Collins and Jeanne Shaheen

Page 16: Medtronic Diabetes - Healthcare Leadership Council ·

Thanks for Your AttentionThanks for Your Attention

| MDT Confidential16